BioCentury
ARTICLE | Company News

Zealand Pharma, Aventis deal

June 30, 2003 7:00 AM UTC

Zealand Pharma granted AVE worldwide rights to its lead compound, ZP10, which is in Phase I/II testing to treat Type II diabetes. The compound is a glucagon-like peptide-1 (GLP-1) receptor agonist. ...